title: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
abstract: BACKGROUND
  Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
  
  
  METHODS
  The HELIOS trial was an international, double-blind, placebo-controlled, phase 3 study in adult patients (≥18 years of age) who had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node disease (>1·5 cm) by CT scan, and had relapsed or refractory disease following one or more previous lines of systemic therapy consisting of at least two cycles of a chemotherapy-containing regimen, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adequate bone marrow, liver, and kidney function. Patients with del(17p) were excluded because of known poor response to bendamustine plus rituximab. Patients who had received previous treatment with ibrutinib or other BTK inhibitors, refractory disease or relapse within 24 months with a previous bendamustine-containing regimen, or haemopoietic stem-cell transplant were also excluded. Patients were randomly assigned (1:1) by a web-based system to receive bendamustine plus rituximab given in cycles of 4 weeks' duration (bendamustine: 70 mg/m(2) intravenously on days 2-3 in cycle 1, and days 1-2 in cycles 2-6; rituximab: 375 mg/m(2) on day 1 of cycle 1, and 500 mg/m(2) on day 1 of cycles 2-6 for a maximum of six cycles) with either ibrutinib (420 mg daily orally) or placebo until disease progression or unacceptable toxicity. Patients were stratified according to whether they were refractory to purine analogues and by number of previous lines of therapy. The primary endpoint was independent review committee (IRC)-assessed progression-free survival. Crossover to ibrutinib was permitted for patients in the placebo group with IRC-confirmed disease progression. Analysis was by intention-to-treat and is continuing for further long-term follow-up. The trial is registered with ClinicalTrials.gov, number NCT01611090.
  
  
  RESULTS
  Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group). The primary endpoint was met at the preplanned interim analysis (March 10, 2015). At a median follow-up of 17 months (IQR 13·7-20·7), progression-free survival was significantly improved in the ibrutinib group compared with the placebo group (not reached in the ibrutinib group (95% CI not evaluable) vs 13·3 months (11·3-13·9) in the placebo group (hazard ratio [HR] 0·203, 95% CI 0·150-0·276; p<0·0001). IRC-assessed progression-free survival at 18 months was 79% (95% CI 73-83) in the ibrutinib group and 24% (18-31) in the placebo group (HR 0·203, 95% CI 0·150-0·276; p<0·0001). The most frequent all-grade adverse events were neutropenia and nausea. 222 (77%) of 287 patients in the ibrutinib group and 212 (74%) of 287 patients in the placebo group reported grade 3-4 events; the most common grade 3-4 adverse events in both groups were neutropenia (154 [54%] in the ibrutinib group vs 145 [51%] in the placebo group) and thrombocytopenia (43 [15%] in each group). A safety profile similar to that previously reported with ibrutinib and bendamustine plus rituximab individually was noted.
  
  
  CONCLUSIONS
  In patients eligible for bendamustine plus rituximab, the addition of ibrutinib to this regimen results in significant improvements in outcome with no new safety signals identified from the combination and a manageable safety profile.
  
  
  BACKGROUND
  Janssen Research & Development.
authors.affiliation: Mayo Clinic Cancer Center, Jacksonville, FL, USA. Electronic address: Chanan-Khan.Asher@mayo.edu.
authors.forename: Asher
authors.initials: A
authors.lastname: Chanan-Khan
authors.affiliation: Department I of Internal Medicine and German CLL Study Group, University of Cologne, Cologne, Germany.
authors.forename: Paula
authors.initials: P
authors.lastname: Cramer
authors.affiliation: Division of Hematology, Dokuz Eylul University, Izmir, Turkey.
authors.forename: Fatih
authors.initials: F
authors.lastname: Demirkan
authors.affiliation: Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
authors.forename: Graeme
authors.initials: G
authors.lastname: Fraser
authors.affiliation: IEP São Lucas/Hemomed Oncologia e Hematologia, São Paulo, Brazil.
authors.forename: Rodrigo Santucci
authors.initials: RS
authors.lastname: Silva
authors.affiliation: Department of Cancer Prevention, Faculty of Public Health, Silesian Medical University, Katowice, Poland.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Grosicki
authors.affiliation: Regional Clinical Hospital, Ryazan, Russia.
authors.forename: Aleksander
authors.initials: A
authors.lastname: Pristupa
authors.affiliation: Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
authors.forename: Ann
authors.initials: A
authors.lastname: Janssens
authors.affiliation: Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Jihlavska, Brno, Czech Republic.
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
authors.affiliation: Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA.
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Bartlett
authors.affiliation: Hôpital Haut-Lévêque, Bordeaux, Pessac, France.
authors.forename: Marie-Sarah
authors.initials: MS
authors.lastname: Dilhuydy
authors.affiliation: Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
authors.forename: Halyna
authors.initials: H
authors.lastname: Pylypenko
authors.affiliation: Hematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Loscertales
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel.
authors.forename: Abraham
authors.initials: A
authors.lastname: Avigdor
authors.affiliation: Department of Haematology, Derriford Hospital, Plymouth, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: Rule
authors.affiliation: Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: Diego
authors.initials: D
authors.lastname: Villa
authors.affiliation: Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia.
authors.forename: Olga
authors.initials: O
authors.lastname: Samoilova
authors.affiliation: 1st Department of Propedeutic Medicine, University of Athens, Athens, Greece.
authors.forename: Panagiots
authors.initials: P
authors.lastname: Panagiotidis
authors.affiliation: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
authors.forename: Andre
authors.initials: A
authors.lastname: Goy
authors.affiliation: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA; Center for CLL, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Anthony
authors.initials: A
authors.lastname: Mato
authors.affiliation: Department of Hematology, Fundaleu, Buenos Aires, Argentina.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Pavlovsky
authors.affiliation: Department of Hematology, Karolinska University Hospital, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Claes
authors.initials: C
authors.lastname: Karlsson
authors.affiliation: Janssen Research & Development, Raritan, NJ, USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Mahler
authors.affiliation: Janssen Research & Development, Raritan, NJ, USA.
authors.forename: Mariya
authors.initials: M
authors.lastname: Salman
authors.affiliation: Janssen Research & Development, Raritan, NJ, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Sun
authors.affiliation: Janssen Research & Development, Raritan, NJ, USA.
authors.forename: Charles
authors.initials: C
authors.lastname: Phelps
authors.affiliation: Janssen Research & Development, Spring House, PA, USA.
authors.forename: Sriram
authors.initials: S
authors.lastname: Balasubramanian
authors.affiliation: Janssen Research & Development, High Wycombe, UK.
authors.forename: Angela
authors.initials: A
authors.lastname: Howes
authors.affiliation: Department I of Internal Medicine, Center of Integrated Oncology, University of Cologne and Cologne Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000139:chemically induced; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D057194:Intention to Treat Analysis; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D010880:Piperidines; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects; D019233:Retreatment; D000069283:Rituximab / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride; D000225:Adenine